Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BYVALSON vs PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Valsartan is an angiotensin II receptor blocker (ARB) that selectively binds to the AT1 receptor, inhibiting angiotensin II-mediated vasoconstriction and aldosterone secretion. It also reduces blood pressure and causes vasodilation.
The drug is a bicarbonate-based peritoneal dialysis solution that buffers metabolic acidosis, removes uremic toxins, and corrects electrolyte imbalances via diffusion and ultrafiltration across the peritoneal membrane. It does not have a traditional receptor-mediated mechanism.
FDA-approved for the treatment of hypertension, heart failure (NYHA class II-IV), and to reduce cardiovascular mortality in stable post-myocardial infarction patients with left ventricular dysfunction or failure.,Off-label uses include diabetic nephropathy, prevention of atrial fibrillation recurrence, and migraine prophylaxis.
FDA-approved for continuous ambulatory peritoneal dialysis (CAPD) and automated peritoneal dialysis (APD) in patients with end-stage renal disease (ESRD),Off-label uses include acute kidney injury (AKI) requiring dialysis in select settings
160 mg orally once daily.
Intravenous infusion only. Each 1000 m L bag contains 4 g of amino acids and 2.5 g of lipids. Typical adult dose: 1.5-2.0 g/kg/day of amino acids (equivalent to 37.5-50 m L/kg/day) and 1.0-1.5 g/kg/day of lipids. Administer at a rate not to exceed 0.11 g/kg/hour of amino acids and 0.15 g/kg/hour of lipids. For a 70 kg patient, this equals approximately 2.6-3.5 L/day.
Terminal half-life 10-12 hours; allows once-daily dosing; extended in severe renal impairment (up to 20 hours)
Calcium: terminal half-life 4-6 hours in patients with normal renal function; magnesium: terminal half-life 3-5 hours. Prolonged in renal impairment.
Valsartan is primarily metabolized by CYP2C9 and minimally by CYP3A4. It undergoes glucuronidation via UGT1A3, UGT1A9, and UGT2B7. The major metabolite is inactive.
The solution components (bicarbonate, lactate, dextrose, electrolytes) are not metabolized by the liver; bicarbonate and lactate are buffer precursors converted via endogenous pathways; dextrose is absorbed and metabolized systemically; electrolytes are regulated by renal and non-renal mechanisms.
Renal: 60% unchanged; Biliary/Fecal: 40% as metabolites; total clearance ~30 L/h
Primarily renal excretion; ~70% of calcium dose and ~60% of magnesium dose excreted unchanged in urine. Fecal elimination accounts for ~20% and ~30%, respectively. Biliary excretion is minimal.
95% bound primarily to albumin
Calcium: ~40-50% bound to albumin; magnesium: ~25-30% bound to albumin. Binding decreases in hypoalbuminemia.
Vd 8-10 L/kg; suggests extensive extravascular distribution
Calcium: 0.25-0.4 L/kg; magnesium: 0.5-0.7 L/kg. Indicates distribution into extracellular fluid and bone (calcium) or intracellular and bone (magnesium).
Oral: 50% (range 40-60%); food reduces peak concentration but not AUC
Intravenous: 100%. Intraperitoneal: ~70-80% (dependent on dwell time and concentration). Oral: ~30-40% for calcium and ~40-60% for magnesium (varies with formulation and GI factors).
No dosage adjustment required for GFR ≥30 m L/min; not recommended for GFR <30 m L/min.
For GFR 30-60 m L/min: reduce amino acid dose to 0.8 g/kg/day. For GFR <30 m L/min: reduce to 0.6 g/kg/day. Lipids may require adjustment based on triglyceride levels. Avoid in severe renal failure unless on dialysis.
Contraindicated in severe hepatic impairment (Child-Pugh class C); no adjustment for mild to moderate impairment (Child-Pugh A or B).
Child-Pugh A: no adjustment. Child-Pugh B: reduce amino acids to 1.0 g/kg/day. Child-Pugh C: avoid use or reduce to 0.5 g/kg/day with close monitoring for encephalopathy. Lipids may be given at standard doses but monitor triglycerides.
Safety and efficacy not established in pediatric patients.
Neonates and infants: amino acids 2.0-3.0 g/kg/day, lipids 1.0-3.0 g/kg/day. Children 1-10 years: amino acids 1.5-2.5 g/kg/day, lipids 1.0-2.0 g/kg/day. Administer via continuous infusion over 24 hours. Monitor serum triglycerides, bilirubin, and liver function.
No specific dose adjustment recommended; initiate cautiously due to potential for decreased renal function.
Use caution; start at low end of adult dosing (amino acids 1.2 g/kg/day, lipids 1.0 g/kg/day). Monitor renal function (creatinine clearance) and fluid status due to increased risk of fluid overload. No specific dose adjustments except based on renal function.
Fetal toxicity: Drugs acting directly on the renin-angiotensin system (RAS) can cause fetal malformations, oligohydramnios, and neonatal renal failure. Discontinue as soon as pregnancy is detected.
Not for intravenous use. Peritoneal dialysis should be performed under strict aseptic technique to prevent peritonitis. Use only in patients with intact peritoneal membrane and no contraindications to peritoneal dialysis.
Hypotension in volume- or salt-depleted patients,Hyperkalemia, especially with renal impairment, diabetes, or concomitant potassium-sparing diuretics,Renal function impairment, including acute renal failure,Angioedema (rare),Use caution in severe aortic stenosis,Avoid concomitant use with aliskiren in diabetic patients
Monitor serum electrolytes, glucose, and acid-base status frequently. Risk of hyperglycemia, hypernatremia, hypokalemia, hypocalcemia, and metabolic alkalosis. Peritonitis and catheter-related infections are major complications. Avoid in patients with severe lactic acidosis or hypokalemia. Use caution in patients with glucose intolerance or liver disease.
Pregnancy (absolute),History of angioedema from any ARB or ACE inhibitor,Concomitant use with aliskiren in diabetic patients (absolute),Severe hepatic impairment (Child-Pugh class C) (relative)
Absolute: Hypersensitivity to any component, pre-existing severe metabolic alkalosis, documented non-functioning peritoneal membrane, or conditions compromising peritoneal integrity (e.g., extensive adhesions, diaphragmatic defects). Relative: Uncontrolled hyperglycemia, severe hypokalemia, or recent abdominal surgery.
Avoid high-potassium foods (e.g., bananas, oranges, spinach, potatoes) and salt substitutes containing potassium chloride, as BYVALSON can increase potassium levels.
No specific food interactions. However, patients should maintain a diet appropriate for chronic kidney disease on peritoneal dialysis, including controlled intake of potassium, phosphorus, and fluids as directed by their healthcare provider.
Angiotensin II receptor antagonists (ARBs) are contraindicated in pregnancy due to fetal renal dysfunction, oligohydramnios, skull ossification defects, and neonatal anuria/hypotension. Risk is highest in the second and third trimesters; first-trimester exposure may also increase risk of congenital malformations.
Limited data; no evidence of teratogenicity in animal studies; avoid if possible in first trimester due to theoretical risks of uremic toxin accumulation.
No data on Byvalson (valsartan/nebivolol) in breast milk. Valsartan is excreted in rat milk; unknown in humans. Nebivolol is likely excreted in human milk. Due to potential for adverse effects in nursing infants (hypotension, bradycardia), breastfeeding is not recommended. M/P ratio not established.
Excreted into breast milk in low amounts; M/P ratio not established; compatible with breastfeeding with monitoring of infant electrolytes.
Byvalson is contraindicated in pregnancy; no dose adjustment is recommended. Alternative antihypertensives with established safety profiles should be used. If exposure occurs, discontinue immediately and manage with appropriate therapy.
Increased plasma volume in pregnancy may require dose adjustments; monitor serum potassium and calcium; hemofiltration dose may need increased frequency or volume.
BYVALSON (sacubitril/valsartan) is a first-in-class ARNI approved for heart failure with reduced ejection fraction (HFr EF). Monitor blood pressure and renal function closely upon initiation, especially in patients on high-dose ACE inhibitors or ARBs. Avoid use with ACE inhibitors within 36 hours due to risk of angioedema. May cause hypotension, hyperkalemia, and renal impairment. Titrate every 2-4 weeks to target dose of 97/103 mg BID as tolerated.
PHOXILLUM BK 4/2.5 is a peritoneal dialysis solution containing 4% icodextrin and 2.5% amino acids. It is used for one exchange per day in continuous ambulatory peritoneal dialysis (CAPD) or automated peritoneal dialysis (APD). Avoid use in patients with known hypersensitivity to icodextrin or amino acids. Monitor serum osmolality and glucose levels, as icodextrin may interfere with glucose oxidase-based glucometers, leading to falsely elevated readings. Use with caution in patients with liver disease due to potential amino acid accumulation.
Do not take within 36 hours of any ACE inhibitor medication.,Take BYVALSON twice daily with or without food.,Monitor blood pressure regularly; report dizziness or fainting.,Avoid salt substitutes containing potassium.,Seek medical help immediately if you experience swelling of the face, lips, or throat.,Stay hydrated but do not use potassium supplements without consulting your doctor.
Use only one bag per day, typically for the long dwell (overnight).,Do not use if the solution is cloudy or the bag is damaged.,Store at room temperature, away from direct sunlight.,Monitor for signs of infection like redness, swelling, or drainage at the catheter site.,Report any unusual abdominal pain or cloudy effluent immediately.,If using a glucose meter, ensure it is not affected by icodextrin; consider using a glucose dehydrogenase-based meter.,Maintain a balanced diet as amino acids may affect protein intake needs.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BYVALSON vs PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER, answered by our medical review team.
BYVALSON is a Angiotensin II Receptor Blocker that works by Valsartan is an angiotensin II receptor blocker (ARB) that selectively binds to the AT1 receptor, inhibiting angiotensin II-mediated vasoconstriction and aldosterone secretion. It also reduces blood pressure and causes vasodilation.. PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER is a Irrigation Solution that works by The drug is a bicarbonate-based peritoneal dialysis solution that buffers metabolic acidosis, removes uremic toxins, and corrects electrolyte imbalances via diffusion and ultrafiltration across the peritoneal membrane. It does not have a traditional receptor-mediated mechanism.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BYVALSON and PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BYVALSON is: 160 mg orally once daily.. The standard adult dose of PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER is: Intravenous infusion only. Each 1000 m L bag contains 4 g of amino acids and 2.5 g of lipids. Typical adult dose: 1.5-2.0 g/kg/day of amino acids (equivalent to 37.5-50 m L/kg/day) and 1.0-1.5 g/kg/day of lipids. Administer at a rate not to exceed 0.11 g/kg/hour of amino acids and 0.15 g/kg/hour of lipids. For a 70 kg patient, this equals approximately 2.6-3.5 L/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BYVALSON and PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BYVALSON is classified as Category C. Angiotensin II receptor antagonists (ARBs) are contraindicated in pregnancy due to fetal renal dysfunction, oligohydramnios, skull ossification defects, and neonatal anuria/hypoten. PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER is classified as Category C. Limited data; no evidence of teratogenicity in animal studies; avoid if possible in first trimester due to theoretical risks of uremic toxin accumulation.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.